2/1/01 conference call notes
1. year 2000 review
(i) direct sales force global expansion
(ii) selling access to data via internet
(iii) sankyo,sumitomo,corning,agilent,sqnm,motorola,perkin-elmer,oxagen deals; 5 academic alliances
(iv) has over 1000 scientists involved in incy-proprietary research through deals and internal efforts
2. 2001 objectives
(i) “ catalyze our internal disease pathway discovery and therapeutic drug research programs”- - say what?? , i.e. more aggressively focus on leveraging their proprietary data in target discovery/ validation and disease markers through a greater number of alliances; specifically mentioned a deal with an antibody company
(ii) a few partners have told them to expect that they may be entering clinical trials in 2001, triggering royalty payments
(iii) approx. 20% top-line growth
(iv) possible pharma deal
(v) begin selling proteome’s data
3. q & a
(i) expects breakeven for 2001
(ii) optimistic that they will probably file for summary judgment in affx case(end 2001 earliest), though at another point, seemed to be talking like they’d settle
4. impressions - - a very skeptical analyst community who still does not buy into the model
sales |
